Interaction of some peroxisome proliferators with the mouse liver peroxisome proliferator-activated receptor (PPAR): a molecular modelling and quantitative structure-activity relationship (QSAR) study

References

• Alvares K., Carrillo A., Yuan P. M., Kawano H., Morimoto R. I., Reddy J. K. Identification of cytosolic peroxisome proliferator binding protein as a member of the heat shock protein HSP 70 family. Proceedings of the National Academy of Sciences, USA 1990; 87: 5293–5297
   PubMed Web of Science ®Google Scholar
• Bell D. R., Bars R. G., Gibson G. G., Elcombe C. R. Localization and differential induction of cytochrome P450IVA and acyl-CoA oxidase in rat liver. Biochemical Journal 1991; 275: 247–252
   PubMed Web of Science ®Google Scholar
• Brandes R., Kaikaus R. M., Lysenko N., Ockner R. K., Bass N. M. Induction of fatty acid binding protein by peroxisome proliferators in primary hepatocyte cultures and its relationship to the induction of peroxisomal β-oxidation. Biochimica et Biophysica Acta 1990; 1034: 53–61
   PubMedGoogle Scholar
• Bronfman M., Amigo L., Morales M. N. Activation of hypolipidaemic drugs to acylcoenzyme A thioesters. Biochemical Journal 1986; 239: 781–784
   PubMed Web of Science ®Google Scholar
• Cannon J. R., Eacho P. I. Interaction of LY 171883 and other peroxisome proliferators with fatty-acid-binding protein isolated from rat liver. Biochemical Journal 1991; 280: 387–391
   PubMedGoogle Scholar
• Clark M., Cramer R. D., Van Opdenbosch N. Validation of the general purpose Tripos 5.2 force field. Journal of Computational Chemistry 1989; 10: 982–1012
   Web of Science ®Google Scholar
• Cohen A. J., Grasso P. Review of the hepatic response to hypolipidaemic drugs in rodents and assessment of its toxicological significance to man. Food and Chemical Toxicology 1981; 19: 585–605
   Web of Science ®Google Scholar
• Dreyer C., Krey G., Keller H., Givel F., Helftenbein G., Wahli W. Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992; 68: 879–887
   PubMed Web of Science ®Google Scholar
• Eacho P. I., Foxworthy P. S. Inhibition of hepatic fatty acyl oxidation by bezafibrate and bezafibroyl CoA. Biochemical and Biophysical Research Communications 1988; 157: 1148–1153
   PubMed Web of Science ®Google Scholar
• Eacho P. I., Foxworthy P. S., Dillard R. D., Whitesitt C. A., Herron D. K., Marshall W. S. Induction of peroxisomal β-oxidation in the rat liver in vivo and in vitro by tetrazole-substituted acetophenones: structure-activity relationships. Toxicology and Applied Pharmacology 1989; 100: 177–184
   PubMedGoogle Scholar
• Elcombe C. R., Mitchell A. M. Peroxisome proliferation due to di(2-ethylhexyl)phthalate (DEHP): species differences and possible mechanisms. Environmental Health Perpsectives 1986; 70: 211–219
   PubMed Web of Science ®Google Scholar
• Evans R. M. The steroid and thyroid hormone receptor superfamily. Science 1988; 240: 889–895
   PubMed Web of Science ®Google Scholar
• Foxworthy P. S., Eacho P. I. Inhibition of hepatic fatty acid oxidation at carnitine palmitoyltransferase I by the peroxisome proliferator 2-hydroxy-3-propyl-4-[6-(tetrazol-5-yl)hexyloxy]acetophenone. Biochemical Journal 1988; 252: 409–414
   PubMedGoogle Scholar
• Gibson G. G. Comparative aspects of the mammalian cytochrome P450IV gene family. Xenobiotica 1989; 19: 1123–1148
   PubMed Web of Science ®Google Scholar
• Godowski P. J., Picard D. Steroid receptors. How to be both a receptor and a transcription factor. Biochemical Pharmacology 1989; 38: 3135–3143
   PubMedGoogle Scholar
• Gotoh O., Tagashira Y., Morohashi K., Fujii-Kuriyama Y. Possible steroid binding site common to adrenal cytochrome P-450SCC and prostatic steroid binding protein. FEBS Letter 1985; 188: 8–10
   PubMedGoogle Scholar
• Gray T. J. B., Lake B. G., Beamand J. A., Foster J. R., Gangolli S. D. Peroxisome proliferation in primary cultures of rat hepatocytes. Toxicology and Applied Pharmacology 1983; 67: 15–25
   PubMed Web of Science ®Google Scholar
• Green S. Receptor-mediated non-genotoxic carcinogenesis: new models for risk assessment?. Human and Experimental Toxicology 1991; 10: 390–395
   PubMedGoogle Scholar
• Green S., Chambon P. Nuclear receptors enhance our understanding of transcription regulation. Trends in Genetics 1988; 4: 309–314
   PubMed Web of Science ®Google Scholar
• Harrison E. H. Action of clofibrate and its analogs in rats: dissociation of hypolipidemic effects and the induction of peroxisomal β-oxidation. Biochimica et Biophysica Acta 1984; 796: 163–168
   PubMedGoogle Scholar
• Issemann I., Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 645–650
   PubMed Web of Science ®Google Scholar
• Kawashima Y., Nakagawa S., Tachibana Y., Kozuka H. Effects of peroxisome proliferators on fatty acid-binding protein in rat liver. Biochimia et Biophysica Acta 1983; 754: 21–27
   PubMedGoogle Scholar
• Lake B. G., Gray T. J. B., Lewis D. F. V., Beamand J. A., Hodder K. D., Purchase R., Gangolli S. D. Structure-activity relationships for induction of peroxisomal enzyme activities by phthalate monoesters in primary rat hepatocyte cultures. Toxicology and Industrial Health 1987; 3: 165–181
   PubMed Web of Science ®Google Scholar
• Lake B. G., Gray Pels T. J. B., Rijcken W. R., Beamand J. A., Gangolli S. D. The effect of hypolipidaemic agents on peroxisomal β-oxidation and mixed-function oxidase activities in primary cultures of rat hepatocytes. Relationship between induction of palmitoyl-CoA oxidation and lauric acid hydroxylation. Xenobiotica 1984; 14: 269–276
   PubMed Web of Science ®Google Scholar
• Lake B. G., Lewis D. F. V., Gray T. J. B. Structure-activity relationships for hepatic peroxisome proliferation. Archives of Toxicology 1988; 217–224, Suppl. 12
   Google Scholar
• Lalwani N. D., Alvares K., Reddy M. K., Reddy M. N., Parikh I., Reddy J. K. Peroxisome proliferator-binding protein: identification and partial characterization of nafenopin-, clofibric acid-, and ciprofibrate-binding proteins from rat liver. Proceedings of the National Academy of Sciences, USA 1987; 84: 5242–5246
   PubMed Web of Science ®Google Scholar
• Lalwani N. D., Fahl W. E., Reddy J. K. Detection of a nafenopin-binding protein in rat liver cytosol associated with the induction of peroxisome proliferation by hypolipidemic compounds. Biochemical and Biophysical Research Communications 1983; 116: 388–393
   PubMed Web of Science ®Google Scholar
• Lewis D. F. V., Lake B. G., Gray T. J. B., Gangolli S. D. Structure activity requirements for induction of peroxisomal enzyme activities in primary rat hepatocyte cultures. Archives of Toxicology 1987; 39–41, Suppl. 11
   Google Scholar
• Lock E. A., Mitchell A. M., Elcombe C. R. Biochemical mechanisms of induction of hepatic peroxisome proliferation. Annual Reviews of Pharmacology and Toxicology 1989; 29: 145–163
   PubMed Web of Science ®Google Scholar
• Milton M. N., Elcombe C. R., Gibson G. G. On the mechanism of induction of microsomal cytochrome P450IVA1 and peroxisome proliferation in rat liver by clofibrate. Biochemical Pharmacology 1990; 40: 2727–2732
   PubMed Web of Science ®Google Scholar
• Milton M. N., Elcombe C. R., Kass G. E. N., Gibson G. G. Lack of evidence for a hepatic peroxisome proliferatoe receptor and an explanation for the binding of hypolipidaemic drugs to liver homogenates. Biochemical Pharmacology 1988; 37: 793–798
   PubMed Web of Science ®Google Scholar
• Mitchell A. M., Lhuguenot J.-C., Bridges J. W., Elcombe C. R. Identification of the proximate peroxisome proliferator(s) derived from di(2-ethylhexyl)phthalate. Toxicology and Applied Pharmacology 1985; 80: 23–32
   PubMed Web of Science ®Google Scholar
• Moody D. E., Reddy J. K., Lake B. G., Popp J. A., Reese D. H. Peroxisome proliferation and nongenotoxic carcinogenesis: commentary on a symposium. Fundamental and Applied Toxicology 1991; 16: 233–248
   PubMed Web of Science ®Google Scholar
• Morncn J. P., Bissery V., Gaboriand C., Thomas A., Ojasoo T., Raynaud J. P. Hydrophobic cluster analysis (HCA) of the hormone-binding domain of receptor proteins. Journal of Steroid Biochemistry 1989; 34: 355–361
   PubMedGoogle Scholar
• Muerhoft A. S., Griffin K. J., Johnson E. F. Evidence that the peroxisome proliferator activated receptor (PPAR) mediates induction of CYP4A6. FASEB Journal 1992; 6, A1202 (Abstract 1534)
   Google Scholar
• Nebert D. W., Nelson D. R., Coon M. J., Estabrook R. W., Fevereisen R., Fujii-Kuriyama Y., Gonsalez F. J., Guengerich F. P., Gunsalus I. C., Johnson E. F., Loper J. C., Sato R., Waterman M. R., Waxman D. J. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA 1991; 10: 1–14
   Google Scholar
• Ojasoo T., Raynaud J.-P., Mornon J.-P. Steroid Hormone Receptors. Comprehensive Medicinal Chemistry, C. Hansch, P. G. Sammes, J. B. Taylor. Pergamon Press, Oxford 1990; Vol. 3: 1175–1226
   Google Scholar
• Orton T. C., Adam H. K., Bentley M., Holloway B., Tucker M. J. Clobuzant: species differences in the morphological and biochemical response of the liver folowing chronic administration. Toxicology and Applied Pharmacology 1984; 73: 138–151
   PubMed Web of Science ®Google Scholar
• Poulos T. L., Finzel B. C., Gunsalus I. C., Wagner G. C., Kraut J. The 2.6 Å crystal structure of Pseudomonas putida cytochrome P-450. Journal of Biological Chemistry 1985; 260: 16122–16130
   PubMed Web of Science ®Google Scholar
• Pourbaix S., Heller F., Harvengt C. Effect of fenofibrate and LF 2151 on hepatic peroxisomes in hamsters. Biochemical Pharmacology 1984; 33: 3661–3666
   PubMed Web of Science ®Google Scholar
• Power R. F., Lydon J. P., Conneely O. M., O'Malley B. W. Dopamine activation of an orphan of the steroid receptor superfamily. Science 1991; 252: 1546–1548
   PubMedGoogle Scholar
• Reddy J. K., Lalwani N. D. Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to man. CRC Critical Reviews in Toxicology 1983; 12: 1–58
   Web of Science ®Google Scholar
• Reddy J. K., Reddy M. K., Usman M. I., Lalwani N. D., Rao M. S. Comparison of hepatic peroxisome proliferative effect and its implication for hepatocarcinogencity of phthalate esters, di(2-ethylhexyl)phthalate, and di(2-ethylhexyl)adipate with a hypolipidemic drug. Environmental Health Perspectives 1986; 65: 317–327
   PubMed Web of Science ®Google Scholar
• Roffey S. J., Walker R., Gibson G. G. Hepatic peroxisomal and microsomal enzyme induction by citral and linalool in rats. Food and Chemical Toxicology 1990; 28: 403–408
   PubMed Web of Science ®Google Scholar
• Sharma R., Lake B. G., Foster J., Gibson G. G. Microsomal cytochrome P-452 induction and peroxisome proliferation by hypolipidaemic agents in rat liver. A mechanistic interrelationship. Biochemical Pharmacology 1988; 37: 1193–1201
   PubMed Web of Science ®Google Scholar
• Thornber C. W. Isosterism and molecular modification in drug design. Chemical Society Reviews 1979; 8: 563–580
   Web of Science ®Google Scholar
• Tugwood J. D., Issemann I., Anderson R. G., Bundell Mc K. R., Pheat W. L., Green S. The mouse peroxisome proliferator activated receptor recognises a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO Journal 1992; 11: 433–439
   PubMed Web of Science ®Google Scholar
• Viswalingham A., Hotchkiss S. A., Goldin R., Rose S., O'Gorman J., Keyhanfar F., Caldwell J. Dose-response relationships for the peroxisomal enzyme induction and peroxisome proliferation produced by dietary cinnamyl anthranilate in the B6C3F1 mouse. Human and Experimental Toxicology 1990; 9: 339–340
   Google Scholar